You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
The lntellis™ with AdaptiveStim™ rechargeable neurostimulator is powered by proprietary Overdrive™ battery technology. It is designed to overcome limitations with other SCS systems and is optimized for the increased energy demands of High Dose (HD) therapy.
Medtronic is the only SCS manufacturer to offer this proprietary, nontraditional lithium ion battery chemistry.
from empty to full
than traditional lithium ion batteries*
a completely discharged device
at 9 years1, independent of therapy parameters or recharge preferences
provides versatility and patient comfort
due to flipped batteries or over-discharged batteries
including optimization for increased energy demands of HD therapies
Our Overdrive™ battery technology has a proprietary chemistry compared with SCS competitor batteries that are based on conventional Li ion chemistry. Our design allows for rapid recharge with minimal impact to the battery capacity at 9 years of use even with full discharge.
Under daily, empty-to-full charge and discharge testing:
Thus, patients will have a more consistent recharge interval and faster recharge experience, even under the most aggressive stimulation conditions.
DTM™ SCS therapy is a proprietary therapy inspired by science and rooted in pre-clinical research, and adapted to provide superior clinical outcomes.
The DTM™ SCS 12-month RCT proved sustained superiority compared to conventional stimulation.3
Access prescriber, implant, MRI, and other manuals on the Medtronic Manual Library. Search by the product name (Intellis™) or model number (97715).
Compared to traditional lithium ion batteries
Descriptive comparison, including studies with similar design (RCT; randomization >100 subjects; comparing 2 SCS therapies; with at least 12-months follow up) and patient populations (inclusion/exclusion criteria; baseline demographics) with back pain responder rates reported. This is not based on a statistical analysis of outcomes between studies.
Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.™
R131649 RS2 Lithium-Ion Overdrive™ Rechargeable Battery DVT Report
Chao Hu, et. al. Remaining useful life assessment of lithium-ion batteries in implantable medical devices. Journal of Power Sources. January 31, 2018, Volume 375, pgs118-130.
Fishman M, Cordner H, Justiz R, et al. 12-Month Results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1–12. doi: 10.1111/papr.13066.
Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537.
See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. [If using an MRI SureScan™ device, see the MRI SureScan™ technical manual before performing an MRI].
For further information, contact your local Medtronic representative.